Riskpilot← Back to searchSign inGet full accessEpharma AB
ABActiveOrg 5592525231Apoteksvägen 82Retail sale of pharmaceutical products · NACE 4773Est. 202010-19 employees
Revenue 2025
SEK 4,3M
-5% vs 2024
EBITDA margin
17.9%
+6% vs 2024
Equity ratio
57.4%
Financial strength
Net profit 2025
SEK 426K
-16% vs 2024
| Revenue | SEK 4,3M | -5% |
| EBITDA | SEK 779K | +6% |
| Net profit | SEK 426K | -16% |
| Total assets | SEK 2,1M | +42% |
| Equity | SEK 1,2M | +12% |
| Employees | — | — |
Legal name
Epharma AB
Org number
5592525231
Legal form
Aktiebolag
NACE code
4773 · Retail sale of pharmaceutical products
Founded
16 april 2020
Share capital
SEK 25 000
Employees
10-19
VAT registered
Yes
Audit selected
No
Last report
2025-03-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget ska bedriva konsultativ verksamhet inom hälsa, rådgivning och läkemedelsdistribution samt därmed förenlig verksamhet. Bolaget ska även äga, förvalta och bedriva handel med värdepapper.
Address
Apoteksvägen 82
Email
fredrik.engman@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 417 | 1 968 | 2 528 | 4 581 | 4 345 |
| Staff expenses | — | −1 018 | −2 215 | −3 276 | −2 546 |
| EBITDA | 231 | 864 | 75 | 732 | 779 |
| Depreciation & amort. | −74 | −74 | −127 | −95 | −71 |
| EBIT | 157 | 790 | −52 | 637 | 708 |
| Net financials | −9 | −4 | −1 | 4 | 13 |
| Profit before tax | 110 | 589 | 2 | 641 | 539 |
| Tax | −24 | −122 | −2 | −133 | −113 |
| Net profit | 86 | 467 | 0 | 508 | 426 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 564 | 1 439 | 969 | 1 489 | 2 114 |
| Equity | 111 | 578 | 579 | 1 087 | 1 213 |
| Long-term debt | 330 | 0 | — | — | — |
| Short-term debt | 85 | 626 | 211 | 222 | 538 |
| Total debt | 415 | 626 | 211 | 222 | 538 |
EBITDA margin
17.9%
This company
15.8%
Market median
+13% vs market
20212025
Equity ratio
57.4%
This company
38.2%
Market median
+50% vs market
20212025
Return on equity
35.1%
This company
18.4%
Market median
+91% vs market
20212025
Net profit margin
9.8%
This company
8.1%
Market median
+21% vs market
20212025
Asset turnover
2.06×
This company
1.12×
Market median
+84% vs market
20212025
Debt / equity
0.74×
This company
0.62×
Market median
+19% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-04-01 – 2025-03-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-04-01 – 2024-03-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-04-01 – 2023-03-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-04-01 – 2022-03-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-04-01 – 2021-03-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
NR Audit | Audit | 2026 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2022 | — | — | |
| Deputy Board Member | 2022 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Epharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Niklas Rudolf Feiff | Audit | 0 companies |
| Fredrik Karl Olof Engman | Board of Directors | 0 companies |
| Göran Olof Engman | Deputy Board Member | 0 companies |